Intrinsic value of Hologic - HOLX

Previous Close

$41.94

  Intrinsic Value

$23.83

stock screener

  Rating & Target

sell

-43%

Previous close

$41.94

 
Intrinsic value

$23.83

 
Up/down potential

-43%

 
Rating

sell

We calculate the intrinsic value of HOLX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 11.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.20
  2.48
  2.73
  2.96
  3.16
  3.35
  3.51
  3.66
  3.79
  3.92
  4.02
  4.12
  4.21
  4.29
  4.36
  4.42
  4.48
  4.53
  4.58
  4.62
  4.66
  4.69
  4.72
  4.75
  4.78
  4.80
  4.82
  4.84
  4.85
  4.87
Revenue, $m
  3,126
  3,204
  3,291
  3,389
  3,496
  3,613
  3,740
  3,876
  4,024
  4,181
  4,349
  4,529
  4,719
  4,922
  5,136
  5,363
  5,604
  5,858
  6,126
  6,409
  6,708
  7,023
  7,354
  7,704
  8,072
  8,459
  8,867
  9,296
  9,747
  10,221
Variable operating expenses, $m
  2,507
  2,554
  2,608
  2,667
  2,733
  2,804
  2,882
  2,966
  3,056
  3,152
  2,660
  2,770
  2,887
  3,010
  3,142
  3,281
  3,428
  3,583
  3,747
  3,920
  4,103
  4,296
  4,499
  4,712
  4,937
  5,174
  5,424
  5,686
  5,962
  6,252
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,507
  2,554
  2,608
  2,667
  2,733
  2,804
  2,882
  2,966
  3,056
  3,152
  2,660
  2,770
  2,887
  3,010
  3,142
  3,281
  3,428
  3,583
  3,747
  3,920
  4,103
  4,296
  4,499
  4,712
  4,937
  5,174
  5,424
  5,686
  5,962
  6,252
Operating income, $m
  620
  650
  684
  721
  763
  808
  858
  911
  968
  1,029
  1,689
  1,758
  1,833
  1,911
  1,994
  2,083
  2,176
  2,275
  2,379
  2,489
  2,605
  2,727
  2,856
  2,991
  3,134
  3,285
  3,443
  3,610
  3,785
  3,969
EBITDA, $m
  1,461
  1,497
  1,538
  1,584
  1,634
  1,688
  1,748
  1,812
  1,880
  1,954
  2,033
  2,116
  2,206
  2,300
  2,400
  2,507
  2,619
  2,738
  2,863
  2,995
  3,135
  3,282
  3,437
  3,600
  3,772
  3,953
  4,144
  4,344
  4,555
  4,777
Interest expense (income), $m
  868
  181
  187
  194
  202
  211
  221
  232
  243
  256
  270
  284
  299
  316
  333
  352
  372
  393
  415
  438
  462
  488
  516
  545
  575
  607
  641
  677
  714
  753
  795
Earnings before tax, $m
  439
  462
  489
  519
  552
  587
  626
  667
  712
  760
  1,405
  1,459
  1,517
  1,578
  1,642
  1,711
  1,783
  1,860
  1,941
  2,026
  2,116
  2,211
  2,311
  2,416
  2,527
  2,644
  2,766
  2,896
  3,031
  3,174
Tax expense, $m
  118
  125
  132
  140
  149
  159
  169
  180
  192
  205
  379
  394
  409
  426
  443
  462
  482
  502
  524
  547
  571
  597
  624
  652
  682
  714
  747
  782
  818
  857
Net income, $m
  320
  338
  357
  379
  403
  429
  457
  487
  520
  555
  1,026
  1,065
  1,107
  1,152
  1,199
  1,249
  1,302
  1,358
  1,417
  1,479
  1,545
  1,614
  1,687
  1,764
  1,845
  1,930
  2,019
  2,114
  2,213
  2,317

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  8,162
  8,365
  8,593
  8,847
  9,127
  9,433
  9,764
  10,121
  10,505
  10,917
  11,356
  11,824
  12,322
  12,850
  13,410
  14,003
  14,631
  15,294
  15,995
  16,734
  17,514
  18,336
  19,202
  20,114
  21,075
  22,086
  23,151
  24,271
  25,449
  26,687
Adjusted assets (=assets-cash), $m
  8,162
  8,365
  8,593
  8,847
  9,127
  9,433
  9,764
  10,121
  10,505
  10,917
  11,356
  11,824
  12,322
  12,850
  13,410
  14,003
  14,631
  15,294
  15,995
  16,734
  17,514
  18,336
  19,202
  20,114
  21,075
  22,086
  23,151
  24,271
  25,449
  26,687
Revenue / Adjusted assets
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
Average production assets, $m
  3,386
  3,470
  3,564
  3,670
  3,786
  3,913
  4,050
  4,198
  4,358
  4,528
  4,710
  4,904
  5,111
  5,330
  5,562
  5,808
  6,069
  6,344
  6,634
  6,941
  7,264
  7,605
  7,965
  8,343
  8,742
  9,161
  9,603
  10,067
  10,556
  11,070
Working capital, $m
  231
  237
  244
  251
  259
  267
  277
  287
  298
  309
  322
  335
  349
  364
  380
  397
  415
  433
  453
  474
  496
  520
  544
  570
  597
  626
  656
  688
  721
  756
Total debt, $m
  3,466
  3,598
  3,746
  3,912
  4,094
  4,293
  4,509
  4,741
  4,991
  5,259
  5,545
  5,850
  6,174
  6,518
  6,882
  7,269
  7,677
  8,109
  8,565
  9,046
  9,554
  10,089
  10,653
  11,247
  11,872
  12,531
  13,223
  13,952
  14,719
  15,526
Total liabilities, $m
  5,314
  5,445
  5,594
  5,760
  5,942
  6,141
  6,356
  6,589
  6,839
  7,107
  7,393
  7,697
  8,021
  8,365
  8,730
  9,116
  9,525
  9,957
  10,412
  10,894
  11,401
  11,936
  12,500
  13,094
  13,720
  14,378
  15,071
  15,800
  16,567
  17,374
Total equity, $m
  2,849
  2,919
  2,999
  3,088
  3,185
  3,292
  3,408
  3,532
  3,666
  3,810
  3,963
  4,127
  4,300
  4,485
  4,680
  4,887
  5,106
  5,338
  5,582
  5,840
  6,112
  6,399
  6,701
  7,020
  7,355
  7,708
  8,080
  8,470
  8,882
  9,314
Total liabilities and equity, $m
  8,163
  8,364
  8,593
  8,848
  9,127
  9,433
  9,764
  10,121
  10,505
  10,917
  11,356
  11,824
  12,321
  12,850
  13,410
  14,003
  14,631
  15,295
  15,994
  16,734
  17,513
  18,335
  19,201
  20,114
  21,075
  22,086
  23,151
  24,270
  25,449
  26,688
Debt-to-equity ratio
  1.220
  1.230
  1.250
  1.270
  1.290
  1.300
  1.320
  1.340
  1.360
  1.380
  1.400
  1.420
  1.440
  1.450
  1.470
  1.490
  1.500
  1.520
  1.530
  1.550
  1.560
  1.580
  1.590
  1.600
  1.610
  1.630
  1.640
  1.650
  1.660
  1.670
Adjusted equity ratio
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  320
  338
  357
  379
  403
  429
  457
  487
  520
  555
  1,026
  1,065
  1,107
  1,152
  1,199
  1,249
  1,302
  1,358
  1,417
  1,479
  1,545
  1,614
  1,687
  1,764
  1,845
  1,930
  2,019
  2,114
  2,213
  2,317
Depreciation, amort., depletion, $m
  841
  848
  855
  862
  871
  880
  890
  901
  912
  925
  344
  358
  373
  389
  406
  424
  443
  463
  484
  507
  530
  555
  581
  609
  638
  669
  701
  735
  770
  808
Funds from operations, $m
  1,162
  1,185
  1,212
  1,241
  1,274
  1,309
  1,347
  1,388
  1,432
  1,479
  1,369
  1,423
  1,480
  1,541
  1,605
  1,673
  1,745
  1,821
  1,901
  1,986
  2,075
  2,169
  2,268
  2,373
  2,483
  2,599
  2,720
  2,849
  2,983
  3,125
Change in working capital, $m
  5
  6
  6
  7
  8
  9
  9
  10
  11
  12
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  22
  23
  25
  26
  27
  29
  30
  32
  33
  35
Cash from operations, $m
  1,157
  1,179
  1,205
  1,234
  1,266
  1,300
  1,338
  1,378
  1,421
  1,468
  1,357
  1,410
  1,466
  1,526
  1,589
  1,656
  1,727
  1,802
  1,881
  1,965
  2,053
  2,146
  2,244
  2,347
  2,456
  2,570
  2,690
  2,817
  2,950
  3,090
Maintenance CAPEX, $m
  -242
  -247
  -253
  -260
  -268
  -276
  -286
  -296
  -306
  -318
  -331
  -344
  -358
  -373
  -389
  -406
  -424
  -443
  -463
  -484
  -507
  -530
  -555
  -581
  -609
  -638
  -669
  -701
  -735
  -770
New CAPEX, $m
  -72
  -84
  -95
  -105
  -116
  -127
  -137
  -148
  -159
  -171
  -182
  -194
  -206
  -219
  -232
  -246
  -260
  -275
  -291
  -307
  -323
  -341
  -359
  -378
  -399
  -420
  -441
  -464
  -489
  -514
Cash from investing activities, $m
  -314
  -331
  -348
  -365
  -384
  -403
  -423
  -444
  -465
  -489
  -513
  -538
  -564
  -592
  -621
  -652
  -684
  -718
  -754
  -791
  -830
  -871
  -914
  -959
  -1,008
  -1,058
  -1,110
  -1,165
  -1,224
  -1,284
Free cash flow, $m
  843
  848
  857
  868
  882
  897
  915
  934
  956
  979
  844
  872
  902
  934
  968
  1,004
  1,043
  1,084
  1,128
  1,174
  1,223
  1,275
  1,329
  1,387
  1,448
  1,512
  1,580
  1,651
  1,727
  1,806
Issuance/(repayment) of debt, $m
  119
  132
  149
  166
  182
  199
  216
  233
  250
  268
  286
  305
  324
  344
  365
  386
  409
  432
  456
  481
  508
  535
  564
  594
  625
  658
  693
  729
  767
  807
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  119
  132
  149
  166
  182
  199
  216
  233
  250
  268
  286
  305
  324
  344
  365
  386
  409
  432
  456
  481
  508
  535
  564
  594
  625
  658
  693
  729
  767
  807
Total cash flow (excl. dividends), $m
  962
  980
  1,006
  1,034
  1,064
  1,096
  1,130
  1,167
  1,206
  1,247
  1,130
  1,177
  1,226
  1,278
  1,332
  1,390
  1,451
  1,516
  1,584
  1,655
  1,730
  1,810
  1,893
  1,981
  2,074
  2,171
  2,273
  2,380
  2,493
  2,612
Retained Cash Flow (-), $m
  -64
  -71
  -80
  -89
  -98
  -107
  -116
  -125
  -134
  -144
  -153
  -163
  -174
  -184
  -196
  -207
  -219
  -231
  -244
  -258
  -272
  -287
  -302
  -318
  -335
  -353
  -371
  -391
  -411
  -432
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  898
  910
  926
  945
  966
  989
  1,015
  1,042
  1,072
  1,103
  977
  1,013
  1,052
  1,093
  1,137
  1,183
  1,232
  1,284
  1,339
  1,397
  1,458
  1,523
  1,591
  1,663
  1,738
  1,818
  1,901
  1,990
  2,082
  2,180
Discount rate, %
  9.10
  9.56
  10.03
  10.53
  11.06
  11.61
  12.19
  12.80
  13.44
  14.12
  14.82
  15.56
  16.34
  17.16
  18.02
  18.92
  19.86
  20.86
  21.90
  23.00
  24.15
  25.35
  26.62
  27.95
  29.35
  30.82
  32.36
  33.97
  35.67
  37.46
PV of cash for distribution, $m
  823
  758
  695
  633
  572
  512
  453
  397
  344
  295
  214
  179
  147
  119
  95
  74
  57
  42
  31
  22
  16
  11
  7
  4
  3
  2
  1
  1
  0
  0
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

FINANCIAL RATIOS  of  Hologic (HOLX)

Valuation Ratios
P/E Ratio 15.3
Price to Sales 3.8
Price to Book 4.1
Price to Tangible Book
Price to Cash Flow 1443.2
Price to Free Cash Flow -115.5
Growth Rates
Sales Growth Rate 8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 9.1%
Cap. Spend. - 3 Yr. Gr. Rate 6.2%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity 78.8%
Total Debt to Equity 120.2%
Interest Coverage 2
Management Effectiveness
Return On Assets 16.9%
Ret/ On Assets - 3 Yr. Avg. 8.8%
Return On Total Capital 13%
Ret/ On T. Cap. - 3 Yr. Avg. 7%
Return On Equity 30.7%
Return On Equity - 3 Yr. Avg. 17.6%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 53%
Gross Margin - 3 Yr. Avg. 53.7%
EBITDA Margin 83.3%
EBITDA Margin - 3 Yr. Avg. 50.6%
Operating Margin 44.7%
Oper. Margin - 3 Yr. Avg. 26.1%
Pre-Tax Margin 40.2%
Pre-Tax Margin - 3 Yr. Avg. 20.5%
Net Profit Margin 24.7%
Net Profit Margin - 3 Yr. Avg. 13.8%
Effective Tax Rate 38.6%
Eff/ Tax Rate - 3 Yr. Avg. 28.1%
Payout Ratio 0%

HOLX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HOLX stock intrinsic value calculation we used $3058.8 million for the last fiscal year's total revenue generated by Hologic. The default revenue input number comes from 0001 income statement of Hologic. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HOLX stock valuation model: a) initial revenue growth rate of 2.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 9.1%, whose default value for HOLX is calculated based on our internal credit rating of Hologic, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Hologic.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HOLX stock the variable cost ratio is equal to 80.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for HOLX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Hologic.

Corporate tax rate of 27% is the nominal tax rate for Hologic. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HOLX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HOLX are equal to 108.3%.

Life of production assets of 13.7 years is the average useful life of capital assets used in Hologic operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HOLX is equal to 7.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2784.7 million for Hologic - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 273.011 million for Hologic is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Hologic at the current share price and the inputted number of shares is $11.5 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 234.19 199.97  hold
DHR Danaher 100.40 86.30  hold
BDX Becton Dickins 231.45 1,279.12  str.buy
BSX Boston Scienti 35.80 12.09  str.sell
COO Cooper 249.97 429.58  str.buy
DGX Quest Diagnost 85.48 117.37  hold

COMPANY NEWS

▶ Is Hologic, Inc. (HOLX) A Good Stock To Buy?   [Dec-13-18 11:30PM  Insider Monkey]
▶ Heres What We Think About Hologic, Inc.s (NASDAQ:HOLX) CEO Pay   [Dec-11-18 01:31PM  Simply Wall St.]
▶ Hologic Launches Three-in-One Omni Hysteroscope   [Dec-10-18 08:07AM  Business Wire]
▶ Ludwig N. Hantson Elected to Hologic Board of Directors   [Nov-19-18 04:03PM  Business Wire]
▶ Hologic (HOLX) Misses Q4 Earnings Estimates   [Nov-07-18 05:40PM  Zacks]
▶ Hologic: Fiscal 4Q Earnings Snapshot   [04:50PM  Associated Press]
▶ Calculating The Fair Value Of Hologic Inc (NASDAQ:HOLX)   [Oct-09-18 03:13PM  Simply Wall St.]
▶ Hologic CEO on fighting breast cancer   [07:37AM  CNBC Videos]
▶ Insulet names its female president as next CEO   [Sep-10-18 09:52PM  American City Business Journals]
▶ 7 Bargain Stocks in Today's Pricey Market   [Aug-14-18 04:34PM  Kiplinger]
▶ Nielsen and Sysco climb while VF and Dycom slip   [Aug-13-18 04:32PM  Associated Press]
▶ This Medtech Beat Quarterly Views So Why Is It Toppling?   [Aug-01-18 04:21PM  Investor's Business Daily]
▶ Hologic CEO on innovating in women's health   [08:08AM  Fox Business Videos]
▶ Hologic: Fiscal 3Q Earnings Snapshot   [04:27PM  Associated Press]
▶ Hologic, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ Q3 Earnings Outlook For Hologic   [08:09AM  Benzinga]
▶ MARKETS: Here's why tech stocks are getting whacked again   [Jul-30-18 01:25PM  Yahoo Finance Video]
▶ 7 S&P 500 Companies Whose Debt Scares Me   [Jul-06-18 01:30PM  InvestorPlace]
▶ Is It The Right Time To Buy Hologic Inc (NASDAQ:HOLX)?   [Jun-25-18 03:33PM  Simply Wall St.]
▶ Tesla and AIG tumble while Kraft Heinz and Kellogg climb   [May-03-18 04:29PM  Associated Press]
▶ Hologic: Fiscal 2Q Earnings Snapshot   [May-02-18 04:14PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.